Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
5-Methyl 3-(2-methyl-prop-3-yl) 2,6-di-methyl-4-(2-nitro-sophen-yl)pyridine-3,5-dicarboxyl-ate.

Acta crystallographica. Section E, Structure reports online

Chen H, Qu D, Wang QF, Jiang R.
PMID: 21580377
Acta Crystallogr Sect E Struct Rep Online. 2010 Feb 13;66:o619. doi: 10.1107/S1600536810005088.

In the title compound, C(20)H(22)N(2)O(5), a photo-degradation product of the hypertension drug nisoldipine, the dihedral angle between the nitro-sophenyl ring and the pyridine ring is 75.7 (3)°. In the crystal structure, weak C-H⋯O hydrogen bonds help to establish the...

Cite
Chen H, Qu D, Wang QF, et al. 5-Methyl 3-(2-methyl-prop-3-yl) 2,6-di-methyl-4-(2-nitro-sophen-yl)pyridine-3,5-dicarboxyl-ate. Acta Crystallogr Sect E Struct Rep Online. 2010;66:o619doi: 10.1107/S1600536810005088.
Chen, H., Qu, D., Wang, Q. F., & Jiang, R. (2010). 5-Methyl 3-(2-methyl-prop-3-yl) 2,6-di-methyl-4-(2-nitro-sophen-yl)pyridine-3,5-dicarboxyl-ate. Acta crystallographica. Section E, Structure reports online, 66o619. https://doi.org/10.1107/S1600536810005088
Chen, Hui, et al. "5-Methyl 3-(2-methyl-prop-3-yl) 2,6-di-methyl-4-(2-nitro-sophen-yl)pyridine-3,5-dicarboxyl-ate." Acta crystallographica. Section E, Structure reports online vol. 66 (2010): o619. doi: https://doi.org/10.1107/S1600536810005088
Chen H, Qu D, Wang QF, Jiang R. 5-Methyl 3-(2-methyl-prop-3-yl) 2,6-di-methyl-4-(2-nitro-sophen-yl)pyridine-3,5-dicarboxyl-ate. Acta Crystallogr Sect E Struct Rep Online. 2010 Feb 13;66:o619. doi: 10.1107/S1600536810005088. PMID: 21580377; PMCID: PMC2983562.
Copy Download .nbib Format: NLM
Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis.

Oxidative medicine and cellular longevity

Ye J, Wang R, Wang M, Fu J, Zhang Q, Sun G, Sun X.
PMID: 34093960
Oxid Med Cell Longev. 2021 May 21;2021:6643615. doi: 10.1155/2021/6643615. eCollection 2021.

Myocardial ischemia/reperfusion injury (MI/RI) is an urgent problem with a great impact on health globally. However, its pathological mechanisms have not been fully elucidated. Hydroxysafflor yellow A (HSYA) has a protective effect against MI/RI. This study is aimed at...

Cite
Ye J, Wang R, Wang M, et al. Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis. Oxid Med Cell Longev. 2021;2021:6643615doi: 10.1155/2021/6643615.
Ye, J., Wang, R., Wang, M., Fu, J., Zhang, Q., Sun, G., & Sun, X. (2021). Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis. Oxidative medicine and cellular longevity, 20216643615. https://doi.org/10.1155/2021/6643615
Ye, Jingxue, et al. "Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis." Oxidative medicine and cellular longevity vol. 2021 (2021): 6643615. doi: https://doi.org/10.1155/2021/6643615
Ye J, Wang R, Wang M, Fu J, Zhang Q, Sun G, Sun X. Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis. Oxid Med Cell Longev. 2021 May 21;2021:6643615. doi: 10.1155/2021/6643615. eCollection 2021. PMID: 34093960; PMCID: PMC8163549.
Copy Download .nbib Format: NLM
[Development of an in vitro cardiomyocytes cell model for embryotoxicological and pharmacological studies].

ALTEX

Wobus AM, Hescheler J.
PMID: 11178567
ALTEX. 1992;9(2):29-42.

Permanent cell lines of pluripotent embryonic stem cells (ESC) are established from early embryonic stages (blastomeres of 8-cell embryos or blastocysts) of the mouse. We developed an in vitro system for differentiation which allowed the optimal development of ESC...

Cite
Wobus AM, Hescheler J. Entwicklung eines in vitro-Herzzell-Modells für embryotoxikologische und pharmakologische Studien. [Development of an in vitro cardiomyocytes cell model for embryotoxicological and pharmacological studies]. ALTEX. 1992;9(2):29-42
Wobus, A. M., & Hescheler, J. (1992). Entwicklung eines in vitro-Herzzell-Modells für embryotoxikologische und pharmakologische Studien. [Development of an in vitro cardiomyocytes cell model for embryotoxicological and pharmacological studies]. ALTEX, 9(2), 29-42.
Wobus, Anna M., and Hescheler, Jürgen. "Entwicklung eines in vitro-Herzzell-Modells für embryotoxikologische und pharmakologische Studien." [Development of an in vitro cardiomyocytes cell model for embryotoxicological and pharmacological studies]. ALTEX vol. 9,2 (1992): 29-42.
Wobus AM, Hescheler J. Entwicklung eines in vitro-Herzzell-Modells für embryotoxikologische und pharmakologische Studien. [Development of an in vitro cardiomyocytes cell model for embryotoxicological and pharmacological studies]. ALTEX. 1992;9(2):29-42. PMID: 11178567.
Copy Download .nbib Format: NLM
Evaluation of cognitive and psychomotor effects of nisoldipine or placebo in healthy volunteers.

Human psychopharmacology

Ponciano E, Robinson L, Barreto M, Cockle SM, Hindmarch I.
PMID: 12404341
Hum Psychopharmacol. 2000 Mar;15(2):137-142. doi: 10.1002/(SICI)1099-1077(200003)15:2<137::AID-HUP151>3.0.CO;2-F.

The purpose of this study was to compare the cognitive and psychomotor effects of the calcium antagonist nisoldipine with placebo in healthy volunteers over the three-week period of this randomised, double-blind, parallel group trial. Thirty volunteers received either a...

Cite
Ponciano E, Robinson L, Barreto M, et al. Evaluation of cognitive and psychomotor effects of nisoldipine or placebo in healthy volunteers. Hum Psychopharmacol. 2000;15(2):137-142doi: 10.1002/(SICI)1099-1077(200003)15:2<137::AID-HUP151>3.0.CO;2-F.
Ponciano, E., Robinson, L., Barreto, M., Cockle, S. M., & Hindmarch, I. (2000). Evaluation of cognitive and psychomotor effects of nisoldipine or placebo in healthy volunteers. Human psychopharmacology, 15(2), 137-142. https://doi.org/10.1002/(SICI)1099-1077(200003)15:2<137::AID-HUP151>3.0.CO;2-F
Ponciano, E., et al. "Evaluation of cognitive and psychomotor effects of nisoldipine or placebo in healthy volunteers." Human psychopharmacology vol. 15,2 (2000): 137-142. doi: https://doi.org/10.1002/(SICI)1099-1077(200003)15:2<137::AID-HUP151>3.0.CO;2-F
Ponciano E, Robinson L, Barreto M, Cockle SM, Hindmarch I. Evaluation of cognitive and psychomotor effects of nisoldipine or placebo in healthy volunteers. Hum Psychopharmacol. 2000 Mar;15(2):137-142. doi: 10.1002/(SICI)1099-1077(200003)15:2<137::AID-HUP151>3.0.CO;2-F. PMID: 12404341.
Copy Download .nbib Format: NLM
3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitro-phen-yl)pyridine-3,5-dicarboxyl-ate.

Acta crystallographica. Section E, Structure reports online

Chen H, Luo J, Jing LL, Jiang R.
PMID: 21580183
Acta Crystallogr Sect E Struct Rep Online. 2009 Dec 09;66:o86. doi: 10.1107/S1600536809051988.

The title nitro-phenyl pyridine compound, C(20)H(22)N(2)O(6) was synthesized as a degradation product of the hypertension medication nisoldipine. The dihedral angle between the nitro-substituted phenyl ring and the pyridine ring is 75.5 (4)°. There are a number of C-H⋯O inter-actions...

Cite
Chen H, Luo J, Jing LL, et al. 3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitro-phen-yl)pyridine-3,5-dicarboxyl-ate. Acta Crystallogr Sect E Struct Rep Online. 2009;66:o86doi: 10.1107/S1600536809051988.
Chen, H., Luo, J., Jing, L. L., & Jiang, R. (2009). 3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitro-phen-yl)pyridine-3,5-dicarboxyl-ate. Acta crystallographica. Section E, Structure reports online, 66o86. https://doi.org/10.1107/S1600536809051988
Chen, Hui, et al. "3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitro-phen-yl)pyridine-3,5-dicarboxyl-ate." Acta crystallographica. Section E, Structure reports online vol. 66 (2009): o86. doi: https://doi.org/10.1107/S1600536809051988
Chen H, Luo J, Jing LL, Jiang R. 3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitro-phen-yl)pyridine-3,5-dicarboxyl-ate. Acta Crystallogr Sect E Struct Rep Online. 2009 Dec 09;66:o86. doi: 10.1107/S1600536809051988. PMID: 21580183; PMCID: PMC2980128.
Copy Download .nbib Format: NLM
Inhibition of lipid peroxidation by some dihydropyridine derivatives.

Journal of anesthesia

Sakamoto A, Ohnishi ST, Ogawa R.
PMID: 15278473
J Anesth. 1993 Apr;7(2):193-7. doi: 10.1007/s0054030070193.

The efficacy of dihydropyridine derivatives in inhibiting lipid peroxidation was studied using modified Buege and Aust's method. The method first involves keeping a decapitated rat head at 37 degrees C for 30 min in order to induce global ischemia....

Cite
Sakamoto A, Ohnishi ST, Ogawa R. Inhibition of lipid peroxidation by some dihydropyridine derivatives. J Anesth. 1993;7(2):193-7doi: 10.1007/s0054030070193.
Sakamoto, A., Ohnishi, S. T., & Ogawa, R. (1993). Inhibition of lipid peroxidation by some dihydropyridine derivatives. Journal of anesthesia, 7(2), 193-7. https://doi.org/10.1007/s0054030070193
Sakamoto, A, et al. "Inhibition of lipid peroxidation by some dihydropyridine derivatives." Journal of anesthesia vol. 7,2 (1993): 193-7. doi: https://doi.org/10.1007/s0054030070193
Sakamoto A, Ohnishi ST, Ogawa R. Inhibition of lipid peroxidation by some dihydropyridine derivatives. J Anesth. 1993 Apr;7(2):193-7. doi: 10.1007/s0054030070193. PMID: 15278473.
Copy Download .nbib Format: NLM
Nisoldipine was associated with increased risk of MI among hypertensive diabetic patients when compared with enalapril.

Evidence-based cardiovascular medicine

Opie LH.
PMID: 16379832
Evid Based Cardiovasc Med. 1998 Sep;2(3):76. doi: 10.1016/s1361-2611(98)80069-9.

No abstract available.

Cite
Opie LH. Nisoldipine was associated with increased risk of MI among hypertensive diabetic patients when compared with enalapril. Evid Based Cardiovasc Med. 1998;2(3):76doi: 10.1016/s1361-2611(98)80069-9.
Opie, L. H. (1998). Nisoldipine was associated with increased risk of MI among hypertensive diabetic patients when compared with enalapril. Evidence-based cardiovascular medicine, 2(3), 76. https://doi.org/10.1016/s1361-2611(98)80069-9
Opie, L H. "Nisoldipine was associated with increased risk of MI among hypertensive diabetic patients when compared with enalapril." Evidence-based cardiovascular medicine vol. 2,3 (1998): 76. doi: https://doi.org/10.1016/s1361-2611(98)80069-9
Opie LH. Nisoldipine was associated with increased risk of MI among hypertensive diabetic patients when compared with enalapril. Evid Based Cardiovasc Med. 1998 Sep;2(3):76. doi: 10.1016/s1361-2611(98)80069-9. PMID: 16379832.
Copy Download .nbib Format: NLM
Correction: The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension.

The New England journal of medicine

[No authors listed]
PMID: 9791152
N Engl J Med. 1998 Oct 29;339(18):1339. doi: 10.1056/NEJM199810293391821.
Free Article

No abstract available.

Cite
Correction: The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension. N Engl J Med. 1998;339(18):1339doi: 10.1056/NEJM199810293391821.
(1998). Correction: The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension. The New England journal of medicine, 339(18), 1339. https://doi.org/10.1056/NEJM199810293391821
"Correction: The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension." The New England journal of medicine vol. 339,18 (1998): 1339. doi: https://doi.org/10.1056/NEJM199810293391821
Correction: The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension. N Engl J Med. 1998 Oct 29;339(18):1339. doi: 10.1056/NEJM199810293391821. PMID: 9791152.
Copy Download .nbib Format: NLM
Efficacy and Tolerability of Nisoldipine Coat-Core vs Diltiazem Retard in Combination with a Beta-Blocker in Patients with Stable Exertional Angina Pectoris.

Clinical drug investigation

Melcher A, Abelin J, Luurila O.
PMID: 18370494
Clin Drug Investig. 1998;15(5):389-96. doi: 10.2165/00044011-199815050-00003.

A randomised, double-blind, placebo-controlled, parallel-group trial with forced titration study to investigate possible equivalence of efficacy and tolerability between nisoldipine coat-core (CC) 40mg once daily, and diltiazem retard 120mg twice daily, was carried out in 176 patients with stable...

Cite
Melcher A, Abelin J, Luurila O. Efficacy and Tolerability of Nisoldipine Coat-Core vs Diltiazem Retard in Combination with a Beta-Blocker in Patients with Stable Exertional Angina Pectoris. Clin Drug Investig. 1998;15(5):389-96doi: 10.2165/00044011-199815050-00003.
Melcher, A., Abelin, J., & Luurila, O. (1998). Efficacy and Tolerability of Nisoldipine Coat-Core vs Diltiazem Retard in Combination with a Beta-Blocker in Patients with Stable Exertional Angina Pectoris. Clinical drug investigation, 15(5), 389-96. https://doi.org/10.2165/00044011-199815050-00003
Melcher, A, et al. "Efficacy and Tolerability of Nisoldipine Coat-Core vs Diltiazem Retard in Combination with a Beta-Blocker in Patients with Stable Exertional Angina Pectoris." Clinical drug investigation vol. 15,5 (1998): 389-96. doi: https://doi.org/10.2165/00044011-199815050-00003
Melcher A, Abelin J, Luurila O. Efficacy and Tolerability of Nisoldipine Coat-Core vs Diltiazem Retard in Combination with a Beta-Blocker in Patients with Stable Exertional Angina Pectoris. Clin Drug Investig. 1998;15(5):389-96. doi: 10.2165/00044011-199815050-00003. PMID: 18370494.
Copy Download .nbib Format: NLM
Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

El Maghraby GM, Ahmed AA, Osman MA.
PMID: 25685045
Saudi Pharm J. 2015 Jan;23(1):67-74. doi: 10.1016/j.jsps.2014.05.001. Epub 2014 May 12.

The aim of this work is to investigate penetration enhancers in proniosomes as a transdermal delivery system for nisoldipine. This was performed with the goal of optimising the composition of proniosomes as transdermal drug delivery systems. Plain proniosomes comprising...

Cite
El Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J. 2014;23(1):67-74doi: 10.1016/j.jsps.2014.05.001.
El Maghraby, G. M., Ahmed, A. A., & Osman, M. A. (2015). Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 23(1), 67-74. https://doi.org/10.1016/j.jsps.2014.05.001
El Maghraby, Gamal M, et al. "Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 23,1 (2015): 67-74. doi: https://doi.org/10.1016/j.jsps.2014.05.001
El Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J. 2015 Jan;23(1):67-74. doi: 10.1016/j.jsps.2014.05.001. Epub 2014 May 12. PMID: 25685045; PMCID: PMC4310994.
Copy Download .nbib Format: NLM
Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis.

American journal of therapeutics

Shah A, Krol G, Sundaresan P, Lettieri J, Falk R, Lasseter K, Heller AH.
PMID: 11850642
Am J Ther. 1995 Jan;2(1):15-19. doi: 10.1097/00045391-199501000-00004.

The pharmacokinetics of a controlled-release formulation (coat--core) of the calcium channel blocker nisoldipine was investigated in eight subjects with biopsy-proved liver cirrhosis and eight healthy subjects. In Stage I, subjects received a single 10-mg dose to determine if this...

Cite
Shah A, Krol G, Sundaresan P, et al. Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis. Am J Ther. 1995;2(1):15-19doi: 10.1097/00045391-199501000-00004.
Shah, A., Krol, G., Sundaresan, P., Lettieri, J., Falk, R., Lasseter, K., & Heller, A. H. (1995). Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis. American journal of therapeutics, 2(1), 15-19. https://doi.org/10.1097/00045391-199501000-00004
Shah, Anita, et al. "Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis." American journal of therapeutics vol. 2,1 (1995): 15-19. doi: https://doi.org/10.1097/00045391-199501000-00004
Shah A, Krol G, Sundaresan P, Lettieri J, Falk R, Lasseter K, Heller AH. Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis. Am J Ther. 1995 Jan;2(1):15-19. doi: 10.1097/00045391-199501000-00004. PMID: 11850642.
Copy Download .nbib Format: NLM
Nisoldipine Cardioplegia in the Isolated Rabbit Heart.

Journal of cardiovascular pharmacology and therapeutics

Açikel Ü, Hazan E, Sariosmanoglu N, Çatalyürek &Huml;, Silistreli E, Güner G, Saydam N, Tunçok Y, Güven H, Karabay Ö, Oto Ö.
PMID: 10684469
J Cardiovasc Pharmacol Ther. 1997 Oct;2(4):285-290. doi: 10.1177/107424849700200406.

BACKGROUND: The metabolic and hemodynamic effects of nisoldipine supplementation in cardioplegia after ischemic injury were investigated in 13 isolated rabbit hearts. Group 1 consisted of 6 hearts, which received St. Thomas II cardioplegic solution. In group 2, nisoldipine was...

Cite
Açikel Ü, Hazan E, Sariosmanoglu N, et al. Nisoldipine Cardioplegia in the Isolated Rabbit Heart. J Cardiovasc Pharmacol Ther. 1997;2(4):285-290doi: 10.1177/107424849700200406.
Açikel, �. �., Hazan, E., Sariosmanoglu, N., Çatalyürek, &. H. u. m. l. ;., Silistreli, E., Güner, G., Saydam, N., Tunçok, Y., Güven, H., Karabay, �. �., & Oto, �. �. (1997). Nisoldipine Cardioplegia in the Isolated Rabbit Heart. Journal of cardiovascular pharmacology and therapeutics, 2(4), 285-290. https://doi.org/10.1177/107424849700200406
Açikel, et al. "Nisoldipine Cardioplegia in the Isolated Rabbit Heart." Journal of cardiovascular pharmacology and therapeutics vol. 2,4 (1997): 285-290. doi: https://doi.org/10.1177/107424849700200406
Açikel Ü, Hazan E, Sariosmanoglu N, Çatalyürek &Huml;, Silistreli E, Güner G, Saydam N, Tunçok Y, Güven H, Karabay Ö, Oto Ö. Nisoldipine Cardioplegia in the Isolated Rabbit Heart. J Cardiovasc Pharmacol Ther. 1997 Oct;2(4):285-290. doi: 10.1177/107424849700200406. PMID: 10684469.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries